No serious adverse events linked to intranasal therapy were observed in the third cohort of the trial. Credit: Diana Polekhina on Unsplash.

AIM ImmunoTech has reported positive safety data from the third cohort in a Phase I AMP-COV-100 clinical study of its intranasal therapy, Ampligen, as a potential prophylaxis or treatment for Covid-19 and various respiratory viral diseases.

The randomised, double-blind, placebo-controlled trial analysed the safety, tolerability, and biological activity of repeated intranasal doses of Ampligen in healthy participants.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

No serious adverse events linked to intranasal therapy were observed in the third cohort of the trial. The latest safety data is in line with results from the first two cohorts of the trial.

The study, sponsored and funded by AIM, is being carried out by the Centre for Human Drug Research (CHDR) in the Netherlands.

According to the study design, a total of 40 healthy participants were given repeated doses of either Ampligen or a placebo.

Participants in the first cohort were given 75μg Ampligen, the second cohort participants received 200μg Ampligen, and those in the third cohort were administered with a 500μg dose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

At present, the trial is continuing dosing in the fourth cohort, with subjects receiving 1250μg Ampligen.

All the trial participants will be given intranasal doses of the therapy every other day for 13 days, representing a total of seven doses for each individual.

Last month, AIM ImmunoTech reported positive safety data from the second cohort in the Phase I study.

According to previous in vitro modelling at The Institute for Antiviral Research at Utah State University in the US, Ampligen showed the potential to lower SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal dose levels.

The 90% effective concentration of Ampligen noticed in a tissue culture model of normal, human-derived tracheal/bronchial epithelial cells is achievable in humans clinically to possibly lower SARS-CoV-2, the company noted.